How should obesity be managed in adults with BMI ≥30 kg/m² or BMI 27 kg/m² with hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnea?

Obesity Management in Adults

For adults with BMI ≥30 kg/m² or BMI 27-29.9 kg/m² with comorbidities (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea), initiate comprehensive treatment combining lifestyle interventions with anti-obesity medications, prioritizing GLP-1 receptor agonists or tirzepatide as first-line pharmacotherapy, and consider metabolic/bariatric surgery for BMI ≥35 kg/m² or BMI 30-34.9 kg/m² with inadequately controlled type 2 diabetes or severe cardiometabolic disease. 1, 2

Treatment Algorithm

Step 1: Initial Assessment and Lifestyle Intervention

• Implement structured behavioral interventions targeting 5-10% weight loss through:

  • Caloric restriction (individualized deficit, not just "calories in/calories out")
  • Focus on nutrient-dense foods while minimizing ultra-processed foods
  • Physical activity (note: exercise alone typically yields only 2-3 kg loss but critical for maintenance) 1

• Review current medications that may cause weight gain:

  • Antidepressants (mirtazapine, amitriptyline)
  • Antihyperglycemics (glyburide, insulin)
  • Consider alternatives where clinically appropriate 1

Step 2: Pharmacotherapy (If <5% Weight Loss in 3-6 Months)

First-line medication options ranked by efficacy:

1. Tirzepatide (GIP/GLP-1 agonist): 21% mean weight loss at 72 weeks - highest efficacy 1

2. Semaglutide (GLP-1 agonist): 8-15% weight loss 1

3. Liraglutide (GLP-1 agonist): 8-10% weight loss 1

4. Phentermine-topiramate: Moderate efficacy 1, 2

5. Naltrexone-bupropion: Moderate efficacy 1

6. Orlistat: <10% weight loss, limited by gastrointestinal side effects 1, 2

Critical caveat: The 2025 AACE guideline 2 and 2023 JAMA review 1 both support long-term medication use, as obesity is a chronic relapsing disease requiring ongoing treatment for weight maintenance.

Step 3: Metabolic/Bariatric Surgery Consideration

Indications have been expanded:

• BMI ≥40 kg/m²: Standard indication
• BMI ≥35 kg/m²: Regardless of comorbidity presence or severity 2
• BMI 30-34.9 kg/m²: When severe cardiometabolic disease (especially type 2 diabetes or CVD) is inadequately controlled despite optimal medical therapy 2

Expected outcomes:

• Surgical sleeve gastrectomy or Roux-en-Y gastric bypass: 25-30% weight loss at 12 months 1
• Requires multidisciplinary perioperative care and long-term follow-up 2

Step 4: Endoscopic Procedures (Alternative/Adjunctive)

• Intragastric balloon or endoscopic sleeve gastroplasty: 10-13% weight loss at 6 months
• May serve as adjunctive therapy with medications 1, 2
• Less durable than surgery; evidence for long-term benefits currently limited 2

Special Considerations for Your Patient Population

Patients with Obstructive Sleep Apnea

Weight loss directly improves:

• Apnea-hypopnea index
• OSA symptoms
• May reduce positive airway pressure requirements 3

Important: OSA patients often have "silent" cardiovascular phenotypes with fewer typical symptoms but more severe disease 4, 5. Systematic comorbidity screening is essential.

Patients with Type 2 Diabetes

• Lower surgical threshold: BMI 30-34.9 kg/m² with inadequately controlled hyperglycemia warrants metabolic surgery consideration 2
• GLP-1 agonists provide dual benefits: weight loss plus glycemic control
• Weight loss improves HbA1c independent of medication effects 1

Patients with Hypertension/Dyslipidemia

• 10 kg weight loss yields:
  • Blood pressure reduction: -10 mmHg
  • Total cholesterol: -10%
  • LDL cholesterol: -15%
  • Triglycerides: -30%
  • HDL cholesterol: +8% 6

Common Pitfalls to Avoid

1. Treating complications instead of obesity itself: Address the root cause (obesity) alongside managing comorbidities 7

2. Discontinuing medications after initial success: Obesity requires long-term pharmacotherapy for weight maintenance when lifestyle interventions alone are insufficient 1

3. Delaying surgical referral: Don't wait until BMI ≥40; newer thresholds support earlier intervention at BMI 30-35 with severe comorbidities 2

4. Underestimating medication efficacy: Modern GLP-1 agonists and tirzepatide achieve clinically meaningful weight loss (15-21%) approaching endoscopic procedures 1

5. Ignoring weight stigma: Obesity bias impairs quality of life and reduces preventive care utilization, particularly in women 1

Monitoring and Maintenance

• Long-term follow-up is mandatory even after clinical improvement 3
• Combine all modalities: behavioral interventions, nutrition, physical activity, pharmacotherapy, and procedures as appropriate 1
• Multidisciplinary team approach optimizes outcomes 2